Concurrent treatment with verapamil suppresses immune and behavioural response to endogenous cannabinoid anandamide

Human Psychopharmacology

Volumn 12, Issue 5, 1997, Pages 481-487

  Šulcová, Alexandra ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Anandamide; Calcium channel; Endogenous cannabimimetic; Leukocyte phagocytosis; Social behaviour in mice; Verapamil

Indexed keywords

ANANDAMIDE; CANNABINOID RECEPTOR AGONIST; VERAPAMIL;

AGGRESSIVENESS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CALCIUM CURRENT; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKOCYTE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SOCIAL BEHAVIOR;

EID: 0030777624     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1077(199709/10)12:5<481::AID-HUP910>3.0.CO;2-Z     Document Type: Article

References (30)

1. Bouaboula, M., Rinaldi, M., Carayon, P., Carillon, C., Delpech, B., Shire, D., Le Fur, G. and Casellas, P. (1993). Cannabinoid receptor expression in human leukocytes. European Journal of Biochemistry, 214, 173-180.
2. Brown, A. M. (1991). A cellular logic for G protein-coupled ion channel pathways. FASEB Journal, 5, 2175-2179.
3. Caulfield, M. P. and Brown, D. A. (1992). Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. British Journal of Pharmacology, 106, 231-232.
4. Devane, W. A. (1994). New dawn of cannabinoid pharmacology. Trends in Pharmacological Science, 15, 40-41.
5. Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A. and Mechoulam, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949.
6. Ernst, M., Heberer, M. and Fischer, H. (1983). Chemiluminescence measurement of immune cells - A tool in immunobiology and clinical research. Journal of Clinical Chemistry and Clinical Biochemistry, 22, 555-560.
7. Fride, E. and Mechoulam, R. (1993). Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. European Journal of Pharmacology, 231, 313-314.
8. Gebremedhin, D., Cambell, W. S., Hillard, C. J. and Harder, D. (1995). Anandamide inhibits calcium currents in cat cerebral arterial smooth-muscle cells. FASEB Journal, 9(3), A263.
9. Grant, E. C. and Mackintosh, H. A. (1963). A comparison of social postures of some common laboratory rodents. Behaviour, 21, 246-259.
10. Hitchcott, P. K., Zharkovsky, A. and File, S. E. (1992). Concurrent treatment with verapamil prevents diazepam withdrawal-induced anxiety, in the absence of altered calcium flux in cortical synaptosomes. Neuropharmacology, 31(1), 55-60.
11. Howlett, A. C. (1995). Cannabinoid compounds and signal transduction mechanism. In: Cannabinoid Receptors, Pertwee, R. G. (Ed.), Academic Press, London, pp. 167-204.
12. Johnson, D. E., Heald, S. L., Dally, R. D. and Janis, R. A. (1993). Isolation, identification and synthesis of an endogenous arachidonic amide that inhibits calcium channel antagonist 1,4-dihydropyridine binding. Prostaglandins Leukotrienes, and Essential Fatty Acids, 48, 429-437.
13. Knyszynski, A. and Fischer, H. (1981). Circadian fluctuations in the activity of phagocytic cells in blood, spleen, and peritoneal cavity of mice as measured by zymosan-induced chemiluminescence. Journal of Immunology, 127(6), 2508-2511.
14. Mackie, K. and Hille, B. (1992). Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proceedings of the National Academy of Sciences, USA, 89, 3825-3829.
15. Mackie, K., Devane, W. A. and Hille, B. (1993). Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Molecular Pharmacology, 44, 498-503.
16. Masihi, K. N., Brehmer, W., Azuma, I., Lange, W. and Muller, S. (1984). Stimulation of chemiluminescence and resistance against aerogenic influenza virus infection by synthetic muramyl dipeptide combined with trehalose dimycolate. Infection and Immunity, 43(1), 233-237.
17. Mechoulam, R., Hanus, L. and Martin, B. R. (1994). Search for endogenous ligands of the cannabinoid receptor. Biochemical Pharmacology, 48(8), 1537-1544.
18. Mechoulam, R. and Fride, E. (1995). The unpaved road to the endogenous brain cannabinoid ligands, the anandamides. In: Cannabinoid Receptors, Pertwee, R. G. (Ed.), Academic Press, London, pp. 233-258.
19. Miczek, K. and Krsiak, M. (1979). Drug effects on agonistic behavior. Advances in Behavioral Pharmacology, 2, 87-161.
20. Pertwee, R. G. (1995). Pharmacological, physiological and clinical implications of the discovery of cannabinoid receptors: an overview. In: Cannabinoid Receptors, Pertwee, R. G. (Ed.), Academic Press, London, pp. 1-34.
21. Siegel, S. (Ed.) (1956). Nonparametric Statistics for the Behavioural Sciences. McGraw-Hill, New York.
22. 2+ channel. European Journal of Pharmacology, 296(3), 347-350.
23. Smith, P. B., Compton, D. R., Welch, S. P., Razdan, R. K., Mechoulam, R. and Martin, B. R. (1994). The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. Journal of Pharmacology and Experimental Therapeutics, 270, 219-227.
24. Šulcová, A. (1991). Calcium channel blocker verapamil antagonizes anxiolytic effect of diazepam in mice. Homeostasis in Health and Disease, 33(4), 165-167.
25. Šulcová, A. (1996). Concurrent treatment with verapamil decreases immune response to cannabimimetic anandamide. European Neuropsychopharmacology, 6(Suppl. 3), 199.
26. Šulcová, A. and Mechoulam, R. (1995). Behavioural effects of anandamide, a cannabinoid receptor agonists, in mice. Behavioural Pharmacology, 6(Suppl. 1), 92.
27. Šulcová, A., Mechoulam, R. and Fride, E. (1996). Biphasic effects of anandamide. Pharmacology, Biochemistry and Behavior, submitted.
28. Tono-Oka, T., Matsumoto, T., Ueno, N., Yashoki, N. and Matsumoto, S. (1983). Chemiluminescence of whole blood. Application of clinical examination of phagocytic functions of whole blood from various types of disease. Clinical Immunology and Immunopathology, 29, 333-340.
29. Watson, S. and Girdlestone, D. (1994). 1994 receptor and ion channel nomenclature supplement. Trends in Pharmacological Sciences (Suppl. 1), 5th edn. Elsevier, Cambridge.
30. Weeks, I., Sturgess, M. L. and Woodhead, J. S. (1986). Chemiluminescence immunoassay: an overview. Clinical Science, 70, 403.